Tracking No. 7706 2505 6190 Boston Greg Weaver Eloxx Pharmaceuticals, Inc. Los Angeles 303 Wyman Street Suite 300 New York Waltham, MA 02452 San Francisco RE: Lease for Eloxx Pharmaceuticals Inc. at 950 Winter Street, Waltham, Massachusetts...Lease Agreement • March 16th, 2018 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research • Massachusetts
THIS INSTRUMENT IS AN INDENTURE OF LEASE in which the Landlord and the Tenant are the parties hereinafter named, and which relates to space in a certain building (the “Building”) known as, and with an address at, 950 Winter Street, Waltham, Massachusetts 02451.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 16th, 2018 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research • Massachusetts
This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) between Eloxx Pharmaceuticals, Inc. (the “Company”), and Gregory Weaver (the “Executive”) is dated as of March 12, 2018 and shall become effective on March 12, 2018 (the “Effective Date”).
RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • March 16th, 2018 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research
This Research and License Agreement is entered into as of this 29th day of August 2013 (the “Effective Date”), by and among Technion Research and Development Foundation Ltd., a company formed under the laws of Israel, having a place of business at the Technion City, Haifa 32000, Israel (“TRDF”) and Eloxx Pharma Ltd., a company formed under the laws of Israel, having a place of business at 14 Shenkar St. Herzelia, Israel (“Licensee”).
SECOND AMENDMENT TO THE RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • March 16th, 2018 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research
This Second Amendment to Research and License Agreement (the “Second Amendment”) is made by and between The Technion Research & Development Foundation Ltd (“TRDF”) and Eloxx Pharmaceuticals Ltd. (“Licensee” or “Eloxx”).
Confidential FIRST AMENDMENT TO RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • March 16th, 2018 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research
This First Amendment to Research and License Agreement is entered into as of November 26, 2013, by and between Technion Research and Development Foundation Ltd., a company formed under the laws of Israel, having a place of business at the Technion City, Haifa 32000, Israel, and Elmo( Pharmaceuticals Ltd., a company formed under the laws of Israel, having a place of business at 14 Shenkar St. Herzelia, Israel (together, the “Parties”).
ELOXX PHARMACEUTICALS, INC. SHARE OWNERSHIP AND OPTION PLAN (2013) By and between Eloxx Pharmaceuticals, Inc. A Delaware corporation (the “Company”) of the first part and (the “Optionee”) of the second partu.s. Option Agreement • March 16th, 2018 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research • Delaware
Unless otherwise define herein, the terms defined in the Plan and in the U.S. Appendix shall have the same defined meanings in this Option Agreement (the “Option Agreement”).
EIGHTH ADDENDUM TO THE RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • March 16th, 2018 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research
This Eighth Addendum to Research and License Agreement (the “Eighth Addendum”) is made by and between The Technion Research & Development Foundation Ltd. (“TRDF”) and Eloxx Pharmaceuticals Ltd. (“Licensee” or “Eloxx”).
FOURTH ADDENDUM TO THE RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • March 16th, 2018 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research
This Fourth Addendum to Research and license Agreement (the “Fourth Addendum”) is made by and between the Technion Research and Development Foundation Ltd. (“TRDF”) and Eloxx Pharmaceuticals Ltd. (“Licensee” or “Eloxx”).
SIXTH ADDENDUM TO THE RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • March 16th, 2018 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research
This Sixth Addendum to Research and License Agreement (the “Sixth Addendum”) is made by and between The Technion Research & Development Foundation Ltd. (“TRDF”) and Eloxx Pharmaceuticals Ltd. (“Eloxx”).
SECOND ADDENDUM TO THE RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • March 16th, 2018 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research
This Second Addendum to Research and License Agreement (the “Second Addendum”) is made by and between The Technion Research & Development Foundation Ltd. (“TRDF”) and Eloxx Pharmaceuticals Ltd. (“Licensee” or “Eloxx”).
SEVENTH ADDENDUM TO THE RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • March 16th, 2018 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research
This Seventh Addendum to Research and license Agreement (the “Seventh Addendum”) is made by and between the Technion Research and Development Foundation Ltd. (“TRDF”) and Eloxx Pharmaceuticals Ltd. (“Licensee” or “Eloxx”).
THIRD ADDENDUM TO THE RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • March 16th, 2018 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research
This Third Addendum to Research and License Agreement (the “Third Addendum”) is made by and between The Technion Research & Development Foundation Ltd. (“TRDF”) and Eloxx Pharmaceuticals Ltd. (“Licensee” or “Eloxx”).
FIRST ADDENDUM TO THE RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • March 16th, 2018 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research
This First Addendum to Research and License Agreement (the “First Addendum”) is made by and between The Technion Research & Development Foundation Ltd. (“TRDF”) and Eloxx Pharmaceuticals Ltd. (“Licensee” or “Eloxx”).
NINTH ADDENDUM TO THE RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • March 16th, 2018 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research
This Ninth Addendum to Research and License Agreement (the “Ninth Addendum”) is made by and between the Technion Research and Development Foundation Ltd. (“TRDF”) and Eloxx Pharmaceuticals Ltd. (“Licensee” or “Eloxx”).
THIRD AMENDMENT TO THE RESEARCH AD LICENSE AGREEMENTResearch and License Agreement • March 16th, 2018 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research
This Third Amendment to Research and License Agreement (the “Third Amendment”) is made by and between The Technion Research & Development Foundation Ltd (“TRDF”) and Eloxx Pharmaceuticals Ltd. (“Licensee” or “Eloxx”).
MEMORANDUM OF UNDERSTANDINGMemorandum of Understanding • March 16th, 2018 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research • Massachusetts
This Memorandum of Understanding (“Agreement”) is made by and between Silvia Noiman (“Noiman”) and Eloxx Pharmaceuticals (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”).
FIFTH ADDENDUM TO THE RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • March 16th, 2018 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research
This Fifth Addendum to Research and License Agreement (the” Fifth Addendum”} is made by and between The Technion Research & Development Foundation Ltd. (“TRDF”) and Eloxx Pharmaceuticals Ltd. (“Eloxx”).
